Quarterly ResultAug 11, 2026, 04:23 PM
Immunome Q2 Net Loss $(73.1)M; R&D Expenses Up 48%
AI Summary
Immunome Inc. reported a net loss of $(73.1) million for the second quarter of 2026, compared to a net loss of $(43.4) million in the prior year, with no collaboration revenue recognized. Research and development expenses significantly increased by 48% to $59.9 million, and general and administrative expenses rose 82% to $18.3 million. Despite the increased losses, the company maintains a strong liquidity position with $520.0 million in cash, cash equivalents, and marketable securities, which is expected to fund operations for at least 12 months.
Key Highlights
- Q2 2026 net loss was $(73.1) million, compared to $(43.4) million in Q2 2025.
- No collaboration revenue recognized in Q2 2026, down from $4.0 million in Q2 2025.
- Research and development expenses increased 48% to $59.9 million in Q2 2026.
- General and administrative expenses rose 82% to $18.3 million in Q2 2026.
- Cash, cash equivalents, and marketable securities totaled $520.0 million as of June 30, 2026.
- Accumulated deficit reached $(855.1) million as of June 30, 2026.
- Weighted-average shares outstanding increased to 113.3 million in Q2 2026.
Price Impact
More from IMNM